Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples